In this double-blind , placebo-controlled trial , we randomly assigned 486 patients , 18 to 64 years of age , with ADPKD ( estimated glomerular filtration rate [ GFR ] , 25 to 60 ml per minute per 1.73 m ( 2 ) of body-surface area ) to receive an ACE inhibitor ( lisinopril ) and placebo or lisinopril and an ARB ( telmisartan ) , with the doses adjusted to achieve a blood pressure of 110/70 to 130/80 mm Hg .